The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in patients with advanced hematologic malignancies.

Inclusion Criteria:

• Refractory to or relapsed after at least 1 prior treatment regimen;
• Eastern Cooperative Oncology Group (ECOG) score of 0 to 2;
• At least 18 years of age.

Exclusion Criteria:

• Any major surgery, chemotherapy or immunotherapy within the last 21 days (limited palliative radiation is allowed ≥ 2 weeks);
• Autologous hematologic stem cell transplant within 3 months of study entry or Allogeneic hematologic stem cell transplant within 12 months;
• Known hepatitis B virus, hepatitis C virus or HIV infection;
• Previous therapy with GS-1101 (CAL-101), IPI-145 or any drug that specifically inhibits the PI3K or mTOR pathway;